# A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

> **NCT03897868** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 248 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1803
- **DRUG:** Amlodipine
- **DRUG:** Losartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03897868
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-21
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-02-26
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03897868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03897868, "A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03897868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*